Compare AbCellera Biologics Inc (ABCL) vs Western Alliance Bancorporation (WAL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Western Alliance Bancorporation — how do they compare? AbCellera Biologics Inc trades at $7.18 (market cap $2.35B), while Western Alliance Bancorporation trades at $78.78 (market cap $9.01B). The key difference: Western Alliance Bancorporation is far larger — about 3.8× AbCellera Biologics Inc's market cap, and Western Alliance Bancorporation pays a 2.04% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | WAL | |
|---|---|---|
Market Cap | $2.35B | $9.01B |
Sector | Health | Financials |
52-Week High | $8.12 | $96.08 |
52-Week Low | $2.78 | $66.70 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Western Alliance Bancorporation (WAL) trades at $82.50, up 1.18% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with a P/E of 9.6 and net income margin of 25.63%. Recent news highlights business expansion and industry recognition, including a #1 ranking in Arizona by Forbes.
The outlook is positive, driven by earnings momentum and a consensus price target of $90.67, offering ~10% upside. Risks include negative operating cash flow and high interest expenses, but strong institutional buy ratings and recent corporate developments support a favorable investment case for growth-oriented investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →
